Table 2.
Demographic and clinical data from 57 kidney recipients (Tx group), 40 uremic patients (uremic controls), and 14 healthy controls, at baseline before transplantation
| Tx Group | Uremic Controls | Healthy Controls | |
|---|---|---|---|
| n | 57 | 40 | 14 |
| Age, yr | 39 ± 13b | 47 ± 11 | 39 ± 11 |
| Gender, male/female | 38/19 | 27/13 | 9/5 |
| ESRD duration, mo | 24c (0 to 134) | 45 (1 to 168) | - |
| BMI, kg/m2 | 24 ± 4 | 24 ± 4 | 24 ± 3 |
| Waist-hip ratio | 0.92 ± 0.09 | 0.91 ± 0.08 | 0.81 ± 0.08a |
| Ever smoking, n (%) | 27 (47) | 26 (65) | 9 (64) |
| Diagnoses, n (%) | |||
| glomerulonephritis | 28 (49) | 13 (33) | - |
| hypertensive kidney disease | 5 (9) | 11 (28) | - |
| vasculitis | 1 (2) | 1 (3) | - |
| PKD | 3 (5) | 7 (18) | - |
| other/unknown | 20 (35) | 8 (20) | - |
| apoplexi | 3 (5) | 3 (8) | - |
| former Tx | 11 (19) | 10 (25) | - |
| Dialysis status, n (%) | |||
| HD | 28 (49) | 28 (70) | - |
| CAPD | 19 (33) | 9 (27) | - |
| predialysis | 10 (18) | 3 (8) | - |
| first-degree relatives with DM | 2 (4) | 4 (10) | 2 (14) |
| Fasting p-glucose, mmol/L | 5.1 ± 0.5 | 5.1 ± 0.5 | 5.0 ± 0.3 |
| p-glucose at 2 h, mmol/L | 7.4 ± 1 | 7.5 ± 2 | 5.4 ± 1a |
| HbA1c, % | 5.2 ± 0.4 | 5.2 ± 0.4 | 5.2 ± 0.2 |
| ISI | 6.8 ± 4.0 | 7.9 ± 5.1 | 14.7 ± 7.0a |
| ISecr | 36.9 ± 18.5 | 31.4 ± 17.3 | 27 ± 14 |
| SBP, mmHg | 142 ± 21 | 141 ± 24 | 118 ± 10a |
| DBP, mmHg | 85 ± 13 | 83 ± 14 | 73 ± 8a |
| Pulse | 69 ± 11 | 72 ± 11 | 61 ± 10a |
Data are presented as mean ± SD or median (range), unless otherwise noted. Wilcoxon rank sum test or two-sample t test was used where appropriate to test. HD, hemodialysis; CAPD, continuous ambulatory peritoneal dialysis; Tx, transplantation; PKD, polycystic kidney disease; DM, diabetes mellitus; SBP, systolic blood pressure; DBP, diastolic blood pressure.
a
Uremic patients versus healthy controls P < 0.0005.
b
Tx group versus uremic controls P < 0.05.
c
Tx group versus uremic controls P < 0.005.